



AMENDMENTS IN THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (currently amended) A compound according to formula (I):



or a pharmaceutically acceptable salt, solvate, or polymorph thereof, wherein R¹ is H or a C₁-C₄ alkyl group;

R² is a $\text{C}=\text{O}-\text{R}^3$ group, a $\text{P}(\text{O})_2-\text{R}^4$ group or an OR group;
$$\begin{array}{c} \text{O} \\ || \\ \text{R}^2 \end{array}$$
$$\begin{array}{c} \text{O} \\ || \\ \text{P}(\text{O})_2-\text{R}^4 \\ | \\ \text{R}^5 \end{array}$$

R² is a $\text{C}=\text{O}-\text{R}^3$ group, a $\text{P}(\text{O})_2-\text{R}^4$ group or an OR group; wherein
$$\begin{array}{c} \text{O} \\ || \\ \text{R}^2 \end{array}$$
$$\begin{array}{c} \text{O} \\ || \\ \text{P}(\text{O})_2-\text{R}^4 \\ | \\ \text{R}^5 \end{array}$$

O
||
 R^3 is H, a C₁-C₂₀ alkyl group, an OR group, an alkylene ester group -(CH₂)_nC-OR¹⁰, an amine group -NR¹¹R¹² or a ~~(CH₂)_m-group~~ -(CH₂)_m-group where m is 1-3 and forms a ring with R⁶, R is a C₁-C₂₀ alkyl group, an aryl group or an alkylene aryl group, R¹⁰ is a C₁-C₁₀ alkyl group, n is 1 to 20, R¹¹ is selected from H, C₁-C₄ alkyl, aryl, alkylene aryl or an alkylene ester group as described above, and R¹² is selected from H, C₁-C₄ alkyl, aryl, alkylene aryl or an alkylene ester group as described above or is a -(CH₂)_z-group where z is 0 to 2, such that R¹² forms a ring with R⁶, and wherein when one of R¹¹ and R¹² is other than H, the other of R¹¹ or R¹² is H; R⁶ is H, C₁-C₄ alkyl, F, Cl, Br, I, NO₂ or a NR¹³R¹⁴ group where R¹³ is H or a C₁-C₃ alkyl group and R¹⁴ is a -(CH₂)_m- group where m is 0 to 3 and forms a ring with the

O
||
 -C-R^3 group when ~~R3 R³~~ is absent; and each of ~~R7, R8 and R9~~ R^7, R^8 and R^9 is independently selected from H, C₁-C₄ alkyl, F, Cl, Br, I or NO₂, preferably, at least two, and more preferably three of R^7, R^8 and R^9 are H.

2. (currently amended) A ~~The~~ compound of claim 1, ~~or a pharmaceutically acceptable salt, solvate, or polymorph thereof,~~ selected from the group consisting of:

N - (4-Pyridyl) *t*-Butyl Carbamate;
N - (4-Pyridyl) Ethyl Carbamate;
N - (4-Pyridyl) Methyl Carbamate;
N - (4-Pyridyl) Isopropyl Carbamate;
N - (4-Pyridyl) Dodecyl Carbamate;
N - (4-Pyridyl) Benzyl Carbamate;
N - (4-Pyridyl) Benzamide;
N - (4-Pyridyl) Acetamide;
N - (4-Pyridyl) Propionamide;
N - (4-Pyridyl) Trimethylacetamide;

N - (4-Pyridyl) Ethyl Succinamate;
N, N' - (4-Pyridyl) Urea;
N, N' - (3,4-Pyridyl) Urea;
P, P-Diphenyl *N*- (4-Pyridyl) Phosphinamide; and
4-Pyridinyl Phosphoramic acid, Diphenyl Ester; and
a pharmaceutically acceptable salt, solvate, or polymorph thereof.

3. (currently amended) A pharmaceutical composition for the treatment of injured mammalian nerve tissue, comprising a pharmaceutically acceptable carrier and an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, effective in such treatment.

4. (currently amended) A-The pharmaceutical composition of claim 3, wherein the compound ~~of claim 1~~ is selected from the group consisting of:

N - (4-Pyridyl) *t*-Butyl Carbamate;
N - (4-Pyridyl) Ethyl Carbamate;
N - (4-Pyridyl) Methyl Carbamate;
N - (4-Pyridyl) Isopropyl Carbamate;
N - (4-Pyridyl) Dodecyl Carbamate;
N - (4-Pyridyl) Benzyl Carbamate;
N - (4-Pyridyl) Benzamide;
N - (4-Pyridyl) Acetamide;
N - (4-Pyridyl) Propionamide;
N - (4-Pyridyl) Trimethylacetamide;
N - (4-Pyridyl) Ethyl Succinamate;
N, N' - (4-Pyridyl) Urea;
N, N' - (3,4-Pyridyl) Urea;
P, P-Diphenyl *N*- (4-Pyridyl) Phosphinamide; and
4-Pyridinyl Phosphoramic acid, Diphenyl Ester;
and ~~the~~ pharmaceutically acceptable salts, solvates, and polymorphs thereof.

5. Cancelled
6. Cancelled
7. Cancelled
8. Cancelled
9. Cancelled
10. Cancelled
11. Cancelled
12. Cancelled
13. Cancelled
14. Cancelled
15. (New) The compound of claim 1, wherein R¹, R⁶, R⁷, R⁸ and R⁹ are each H; and R² is a -C(O)R³ group, wherein R³ is -OCH₂CH₃.